OTCPK:DGWP.F

Stock Analysis Report

Executive Summary

Drägerwerk AG & Co. KGaA develops equipment and solutions in the fields of medical and safety technology in Europe, the Americas, Africa, Asia, and Australia.

Snowflake

Fundamentals

Flawless balance sheet and undervalued.


Similar Companies

Share Price & News

How has Drägerwerk KGaA's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:DGWP.F

0.5%

US Medical Equipment

-0.02%

US Market


1 Year Return

n/a

OTCPK:DGWP.F

9.9%

US Medical Equipment

1.6%

US Market

No trading data on DGWP.F.

No trading data on DGWP.F.


Share holder returns

DGWP.FIndustryMarket
7 Day0%0.5%-0.02%
30 Day-7.4%0.09%2.7%
90 Dayn/a2.0%1.4%
1 Yearn/a10.8%9.9%3.8%1.6%
3 Year-39.6%-39.6%69.0%63.9%45.2%35.8%
5 Yearn/a136.2%109.3%61.8%44.1%

Price Volatility Vs. Market

How volatile is Drägerwerk KGaA's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Drägerwerk KGaA undervalued based on future cash flows and its price relative to the stock market?

45%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Drägerwerk KGaA's share price is below the future cash flow value, and at a moderate discount (> 20%).

Drägerwerk KGaA's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Drägerwerk KGaA is good value based on earnings compared to the US Medical Equipment industry average.

Drägerwerk KGaA is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Drägerwerk KGaA is good value based on expected growth next year.


Price Based on Value of Assets

Drägerwerk KGaA is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Drägerwerk KGaA expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

26.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Drägerwerk KGaA's revenue is expected to grow by 3.4% yearly, however this is not considered high growth (20% yearly).

Drägerwerk KGaA's earnings are expected to grow significantly at over 20% yearly.

Drägerwerk KGaA's revenue growth is positive but not above the United States of America market average.

Drägerwerk KGaA's earnings growth is expected to exceed the United States of America market average.

Drägerwerk KGaA's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Drägerwerk KGaA is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Drägerwerk KGaA performed over the past 5 years?

-16.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Drägerwerk KGaA's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.

Drägerwerk KGaA's 1-year earnings growth exceeds its 5-year average (6.4% vs -16.7%)

Drägerwerk KGaA's earnings growth has not exceeded the US Medical Equipment industry average in the past year (6.4% vs 28.2%).


Return on Equity

Drägerwerk KGaA has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Drägerwerk KGaA used its assets less efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Drägerwerk KGaA has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Drägerwerk KGaA's financial position?


Financial Position Analysis

Drägerwerk KGaA is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Drägerwerk KGaA's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Drägerwerk KGaA's level of debt (22.1%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (39% vs 22.1% today).

Debt is well covered by operating cash flow (44.7%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 10.8x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 6.2x debt.


Next Steps

Dividend

What is Drägerwerk KGaA's current dividend yield, its reliability and sustainability?

0.81%

Expected Dividend Yield


Dividend Yield and Payments Analysis

Drägerwerk KGaA's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.44%).

Drägerwerk KGaA's dividend is below the markets top 25% of dividend payers in United States of America (3.69%).

Drägerwerk KGaA is not paying a notable dividend for United States of America, therefore no need to check if the payments are stable.

Drägerwerk KGaA is not paying a notable dividend for United States of America, therefore no need to check if the payments are increasing.


Current Payout to Shareholders

No need to calculate the sustainability of Drägerwerk KGaA's dividends as it is not paying a notable one for United States of America.


Future Payout to Shareholders

Dividends after 3 years are expected to be thoroughly covered by earnings (9x coverage).


Next Steps

Management

What is the CEO of Drägerwerk KGaA's salary, the management and board of directors tenure and is there insider trading?

4.3yrs

Average management tenure


CEO

Stefan Dräger (56yo)

14.2yrs

Tenure

€1,526,289

Compensation

Mr. Stefan A. Dräger, Dipl.-Ing. (BA), has been the Chief Executive Officer and Chairman of the Executive Board at Drägerwerk Verwaltungs AG, a General Partner of Dragerwerk AG & Co. KGaA since July 1, 200 ...


CEO Compensation Analysis

Stefan's remuneration is lower than average for companies of similar size in United States of America.

Stefan's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

4.3yrs

Average Tenure

51.5yo

Average Age

The tenure for the Drägerwerk KGaA management team is about average.


Board Age and Tenure

11.3yrs

Average Tenure

60yo

Average Age

The average tenure for the Drägerwerk KGaA board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Welf Böttcher

    Head of Corporate Communications

    • Tenure: 0yrs
  • Stefan Dräger (56yo)

    Chairman of Executive Board & CEO - Drägerwerk Verwaltungs AG

    • Tenure: 14.2yrs
    • Compensation: €1.53m
  • Toni Schrofner (56yo)

    Executive Board Member & Chief Officer Innovation

    • Tenure: 4.4yrs
    • Compensation: €856.13k
  • Gert-Hartwig Lescow (52yo)

    Vice Chairman of Executive Board & CFO - Drägerwerk Verwaltungs AG

    • Tenure: 4.4yrs
    • Compensation: €1.05m
  • Rainer Klug (51yo)

    Executive Board Member of Purchasing

    • Tenure: 4.1yrs
    • Compensation: €828.24k
  • Reiner Piske (49yo)

    Executive Board Member of HR & Member of Executive Board - Drägerwerk Verwaltungs AG

    • Tenure: 3.8yrs
    • Compensation: €694.03k
  • Stephan Kruse (49yo)

    Head of Global Operations & Member of Supervisory Board

    • Tenure: 1.3yrs
    • Compensation: €13.33k

Board Members

  • Thorsten Grenz (61yo)

    Member of Supervisory Board

    • Tenure: 11.3yrs
    • Compensation: €40.00k
  • Stefan Lauer (64yo)

    Chairman

    • Tenure: 1.3yrs
    • Compensation: €50.83k
  • Uwe Lüders (67yo)

    Member of Supervisory Board

    • Tenure: 11.3yrs
    • Compensation: €26.67k
  • Reinhard Zinkann (60yo)

    Member of Supervisory Board

    • Tenure: 11.3yrs
    • Compensation: €20.00k
  • Thomas Rickers (59yo)

    Member of Supervisory Board

    • Tenure: 19.7yrs
    • Compensation: €20.00k
  • Siegfrid Kasang (62yo)

    Vice Chairman of Supervisory Board

    • Tenure: 14.7yrs
    • Compensation: €40.00k
  • Daniel Friedrich (44yo)

    Member of Supervisory Board

    • Tenure: 13yrs
    • Compensation: €30.00k
  • Nike Benten

    Member of Supervisory Board

    • Tenure: 3.6yrs
    • Compensation: €20.00k
  • Bettina van Almsick (60yo)

    Member of Supervisory Board

    • Tenure: 3.3yrs
    • Compensation: €20.00k
  • Stephan Kruse (49yo)

    Head of Global Operations & Member of Supervisory Board

    • Tenure: 1.3yrs
    • Compensation: €13.33k

Company Information

Drägerwerk AG & Co. KGaA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Drägerwerk AG & Co. KGaA
  • Ticker: DGWP.F
  • Exchange: OTCPK
  • Founded: 1889
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €673.176m
  • Listing Market Cap: €744.746m
  • Shares outstanding: 17.76m
  • Website: https://www.draeger.com

Number of Employees


Location

  • Drägerwerk AG & Co. KGaA
  • Moislinger Allee 53-55
  • Lübeck
  • 23558
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DRWK.FOTCPK (Pink Sheets LLC)YesPreferred SharesUSUSDJan 1992
DRW3DB (Deutsche Boerse AG)YesPreferred SharesDEEURJan 1992
DRW5DB (Deutsche Boerse AG)GENUSSSCHEINE EUR25.56 (PERPETUAL) SER.ADEEURJan 1992
DRW3XTRA (XETRA Trading Platform)YesPreferred SharesDEEURJan 1992
0K5ELSE (London Stock Exchange)YesPreferred SharesGBEURJan 1992
DRW3SWX (SIX Swiss Exchange)YesPreferred SharesCHCHFJan 1992
DRW3DBATS-CHIXE (BATS 'Chi-X Europe')YesPreferred SharesGBEURJan 1992
DRW3WBAG (Wiener Boerse AG)YesPreferred SharesATEURJan 1992
DRW7DB (Deutsche Boerse AG)GENUSSSCHEINE EUR25.56 (PERPETUAL) SER.KDEEURNov 1993
DRW1DB (Deutsche Boerse AG)GENUSSSCHEINE EUR25.56 (PERPETUAL) SER.DDEEURSep 1998
DWRK.FOTCPK (Pink Sheets LLC)GENUSSSCHEINE EUR25.56 (PERPETUAL) SER.DUSUSDSep 1998
DGWP.FOTCPK (Pink Sheets LLC)Common SharesUSUSDJun 2010
DRW8DBATS-CHIXE (BATS 'Chi-X Europe')Common SharesGBEURJun 2010
0MT8LSE (London Stock Exchange)Common SharesGBEURJun 2010
DRW8XTRA (XETRA Trading Platform)Common SharesDEEURJun 2010
DRW8DB (Deutsche Boerse AG)Common SharesDEEURJun 2010

Biography

Drägerwerk AG & Co. KGaA develops equipment and solutions in the fields of medical and safety technology in Europe, the Americas, Africa, Asia, and Australia. The company develops, produces, and markets sy ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/19 00:27
End of Day Share Price2019/08/29 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.